| 摘要 |
Disclosed are a prevention/treatment agent for diabetic retinopathy characterized by containing lutein; said prevention/treatment agent, an ameliorating agent for an electroretinogram, an apoptosis suppression agent for retinal ganglion cells, a decrease suppression agent for molecules related to neural transmission, an ERK activation suppression agent, or a decrease suppression agent for brain-derived neurotrophic factors for being administered in the initial stage of diabetic retinopathy including simple retinopathy or preproliferative retinopathy; and a method for determining the dosing period of a prevention/ameliorating agent for diabetic retinopathy by means of comparing measured electroretinogram values with normal measured electroretinogram values, or by means of observing changes in the thicknesses of the inner plexiform layer, the inner granular layer, and the ganglion cell layer of the retina using optical coherence tomography. |
